Cargando…

The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies

Preclinical and clinical tomographic imaging systems increasingly are being utilized for non-invasive imaging of reporter gene products to reveal the distribution of molecular therapeutics within living subjects. Reporter gene and probe combinations can be employed to monitor vectors for gene, viral...

Descripción completa

Detalles Bibliográficos
Autores principales: Penheiter, Alan R, Russell, Stephen J, Carlson, Stephanie K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367315/
https://www.ncbi.nlm.nih.gov/pubmed/22263922
http://dx.doi.org/10.2174/156652312799789235
_version_ 1782234833947197440
author Penheiter, Alan R
Russell, Stephen J
Carlson, Stephanie K
author_facet Penheiter, Alan R
Russell, Stephen J
Carlson, Stephanie K
author_sort Penheiter, Alan R
collection PubMed
description Preclinical and clinical tomographic imaging systems increasingly are being utilized for non-invasive imaging of reporter gene products to reveal the distribution of molecular therapeutics within living subjects. Reporter gene and probe combinations can be employed to monitor vectors for gene, viral, and cell-based therapies. There are several reporter systems available; however, those employing radionuclides for positron emission tomography (PET) or singlephoton emission computed tomography (SPECT) offer the highest sensitivity and the greatest promise for deep tissue imaging in humans. Within the category of radionuclide reporters, the thyroidal sodium iodide symporter (NIS) has emerged as one of the most promising for preclinical and translational research. NIS has been incorporated into a remarkable variety of viral and non-viral vectors in which its functionality is conveniently determined by in vitro iodide uptake assays prior to live animal imaging. This review on the NIS reporter will focus on 1) differences between endogenous NIS and heterologously-expressed NIS, 2) qualitative or comparative use of NIS as an imaging reporter in preclinical and translational gene therapy, oncolytic viral therapy, and cell trafficking research, and 3) use of NIS as an absolute quantitative reporter.
format Online
Article
Text
id pubmed-3367315
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-33673152012-06-05 The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies Penheiter, Alan R Russell, Stephen J Carlson, Stephanie K Curr Gene Ther Article Preclinical and clinical tomographic imaging systems increasingly are being utilized for non-invasive imaging of reporter gene products to reveal the distribution of molecular therapeutics within living subjects. Reporter gene and probe combinations can be employed to monitor vectors for gene, viral, and cell-based therapies. There are several reporter systems available; however, those employing radionuclides for positron emission tomography (PET) or singlephoton emission computed tomography (SPECT) offer the highest sensitivity and the greatest promise for deep tissue imaging in humans. Within the category of radionuclide reporters, the thyroidal sodium iodide symporter (NIS) has emerged as one of the most promising for preclinical and translational research. NIS has been incorporated into a remarkable variety of viral and non-viral vectors in which its functionality is conveniently determined by in vitro iodide uptake assays prior to live animal imaging. This review on the NIS reporter will focus on 1) differences between endogenous NIS and heterologously-expressed NIS, 2) qualitative or comparative use of NIS as an imaging reporter in preclinical and translational gene therapy, oncolytic viral therapy, and cell trafficking research, and 3) use of NIS as an absolute quantitative reporter. Bentham Science Publishers 2012-02 2012-02 /pmc/articles/PMC3367315/ /pubmed/22263922 http://dx.doi.org/10.2174/156652312799789235 Text en © 2012 Bentham Science Publishers http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Penheiter, Alan R
Russell, Stephen J
Carlson, Stephanie K
The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies
title The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies
title_full The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies
title_fullStr The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies
title_full_unstemmed The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies
title_short The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies
title_sort sodium iodide symporter (nis) as an imaging reporter for gene, viral, and cell-based therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367315/
https://www.ncbi.nlm.nih.gov/pubmed/22263922
http://dx.doi.org/10.2174/156652312799789235
work_keys_str_mv AT penheiteralanr thesodiumiodidesymporternisasanimagingreporterforgeneviralandcellbasedtherapies
AT russellstephenj thesodiumiodidesymporternisasanimagingreporterforgeneviralandcellbasedtherapies
AT carlsonstephaniek thesodiumiodidesymporternisasanimagingreporterforgeneviralandcellbasedtherapies
AT penheiteralanr sodiumiodidesymporternisasanimagingreporterforgeneviralandcellbasedtherapies
AT russellstephenj sodiumiodidesymporternisasanimagingreporterforgeneviralandcellbasedtherapies
AT carlsonstephaniek sodiumiodidesymporternisasanimagingreporterforgeneviralandcellbasedtherapies